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Abstract
Background Considering the heavy economic burden of osteoporotic fractures, the limits of healthcare resources, and the
recent availability of new anti-osteoporosis drugs, there is continuing interest in economic evaluation studies of osteoporosis
management strategies.
Objectives This study aims to (1) systematically review recent economic evaluations of drugs for osteoporosis and (2) to
apply an osteoporosis-specific guideline to critically appraise them.
Methods A literature search was undertaken using PubMed, EMBASE, National Health Service Economic Evaluation
database, and the Cost-Effectiveness Analysis Registry to identify original articles containing economic evaluations of
anti-osteoporosis drugs, published between 1 July, 2013 and 31 December, 2019. A recent European Society for Clinical
and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases-International Osteoporosis Foundation (ESCEO-IOF) guideline for the conduct and reporting of economic evaluations in osteoporosis was used to assess the
quality of included articles.
Results The database search retrieved 3860 records, of which 27 studies fulfilled the inclusion criteria. These studies were
conducted in 15 countries; 12 active drugs were assessed, including various traditional pharmacological treatments such as
bisphosphonates, raloxifene, strontium ranelate, denosumab, and teriparatide, and new agents such as abaloparatide, romosozumab, and gastro-resistant risedronate. Eight out of 12 studies that compared traditional oral bisphosphonates to other
active interventions (denosumab, zoledronic acid, gastro-resistant risedronate, and teriparatide) suggested that the other
active agents were generally cost-effective or dominant. Additionally, the cost-effectiveness of sequential therapy has recently
been assessed and indications are that it can lead to extra health benefits (larger gains in quality-adjusted life-year). The key
drivers of cost effectiveness included baseline fracture risk, drug effect on the risk of fractures, drug cost, and medication
adherence/persistence. The current average score for quality assessment was 17 out of 25 (range 2–15); room for improvement was observed for most studies, which could potentially be explained by the fact that most studies were published prior
to the osteoporosis-specific guideline. Greater adherence to guideline recommendations was expected for future studies. The
quality of reporting was also suboptimal, especially with regard to treatment side effects, treatment effect after discontinuation, and medication adherence.
Conclusions This updated review provides an overview of recently published cost-effectiveness analyses. In comparison with
a previous review, recent economic evaluations of anti-osteoporosis drugs were conducted in more countries and included
more active drugs and sequential therapy as interventions/comparators. The updated economic evidence could help decision
makers prioritize health interventions and the unmet/unreported quality issues indicated by the osteoporosis-specific guideline
could be useful in improving the transparency, quality, and comparability of future economic evaluations in osteoporosis.
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Key Points for Decision Makers
In comparison with oral bisphosphonates (including
generic forms), other active interventions (such as denosumab, zoledronic acid, gastro-resistant risedronate, or
teriparatide) were generally cost effective or dominant
Sequential therapy has the potential to generate extra
health benefits and to be cost effective in comparison
with monotherapy, although more clinical and economic
data are needed
Although several studies partially followed the European
Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal DiseasesInternational Osteoporosis Foundation guideline, quality
was largely insufficient for most articles. Our study
highlighted that insufficiently implemented and/or
reported recommendations should be included in future
studies; this could be useful in improving the transparency, quality, and comparability of economic evaluations
in osteoporosis

1 Introduction
Osteoporosis is a skeletal disease associated with a significant health and economic burden, which has become
an increasing global health problem considering the aging
population characterized by multi-morbidity. The morbidity
and mortality imposed by osteoporotic fractures along with
the negative impact on patients’ quality of life are important
clinical considerations [1]. Worldwide, osteoporosis causes
more than 8.9 million fractures annually, resulting in an
osteoporotic fracture every 3 s [2]. In the European Union,
22 million women and 5.5 million men had osteoporosis in
2010 [3]. As a result of changes in population demography,
the annual number of fragility fractures was expected to rise
from 3.5 million in 2010 to 4.5 million in 2025, corresponding to an increase of 28% [4]. In the USA, over 1.5 million
fractures per year were attributable to osteoporosis, resulting
in direct healthcare costs of 12–18 billion US dollars [5].
Improving osteoporosis care and reducing spiraling fracturerelated costs pose worldwide challenges.
Health economic evaluations have become increasingly
important to support the setting of priorities in healthcare
and to help decision makers allocate healthcare resources
efficiently in the context of limited healthcare resources,
the ongoing aging of the population, and the heavy
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economic burden of osteoporotic fractures, as well as the
recent availability of new agents for osteoporosis management (e.g., abaloparatide, romosozumab, gastro-resistant
risedronate). In 2015, a study systematically reviewed
all economic evaluations of anti-osteoporosis drugs published up to 31 June, 2013 and suggested that anti-osteoporosis drugs were generally cost effective in comparison
with no treatment in postmenopausal women aged over
60–65 years with low bone mass, especially those with
prior vertebral fractures. However, given the heterogeneity of fracture risk, comparators, country setting, model
structure, and incorporation of medication adherence, as
well as the lack of head-to-head comparisons, it remained
challenging to make comparisons between studies [6]. In
addition, the quality of reporting was largely insufficient
for most studies, despite the fact that guidelines for conducting health economic evaluations have been widely
available for many years.
Recently, a guideline for the conduct and reporting of
economic evaluations in the field of osteoporosis has been
designed by a working group convened by the European
Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) and the US branch of the International Osteoporosis Foundation (IOF) [7]. Although several diseasespecific recommendations for economic evaluations have
been developed, this guideline is the first that provides a
list of recommendations and minimum requirements for
the design, conduct, and reporting of an osteoporosisspecific economic evaluation. Osteoporosis-specific
recommendations in this guideline, which supplement
general and national guidelines, could guide researchers in designing appropriate and high-quality economic
evaluations and help decision makers and reviewers to
assess the quality of these studies, and further to improve
the transparency and comparability of these studies and
maintain methodologic standards [7]. Therefore, assessing how recent studies adhere to the osteoporosis-specific
guideline is important in identifying the main limitations
of these studies, and further to indicate some of the most
important recommendations that should be taken into
account in future studies.
An overview of currently available studies regarding cost-effectiveness analyses of drugs for osteoporosis
would thus be useful to guide researchers in designing
and conducting high-quality economic evaluations, in
identifying gaps in current evidence, and to help administrators make decisions based on high-quality evidence.
We therefore updated and undertook this review to (1)
systematically identify and review economic evaluations
published between 2013 and 2019 on drugs for osteoporosis and (2) to critically appraise their quality using the
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recent osteoporosis-specific guideline, and also to provide
insight into key drivers of cost-effectiveness ratios.

2 Methods
2.1 Literature Search
A systematic literature search was undertaken to identify
recent cost-effectiveness analyses of drugs for osteoporosis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline
[8]. The search was conducted using several databases
including PubMed, EMBASE (Ovid), National Health
Service Economic Evaluation Database (NHS EED) [the
database ceased to be updated after March 2015] and the
Cost-Effectiveness Analysis (CEA) Registry (the database
can serve as an archive only until 2018). We restricted
our analysis to articles published between 1 July, 2013
and 31 December, 2019, as prior articles were covered in
the previous review [6]. An initial search was conducted
in PubMed and EMBASE using a search strategy (see
Appendix 1 in the Electronic Supplementary Material
[ESM]) designed according to the Population, Intervention, Comparator, Outcome (PICO) criteria with the help
of an expert library specialist. The key word ‘osteoporosis’ was used in the NHS EED and the CEA Registry
database.

2.2 Study Selection
First, duplicates were identified and removed. Second,
two reviewers (NL, DC) independently applied inclusion
and exclusion criteria to screen titles and abstracts of the
remaining articles. Third, full-text versions of eligible articles were screened in-depth by two independent reviewers
(NL and DC, LS, DP, SS, or RB). A consensus meeting
with a third reviewer (MH) was used to resolve discrepancies. Finally, reference lists and citations of eligible articles were checked manually for additional relevant studies.
Studies were included if they were published in English between July 2013 and December 2019 and contained
a full economic evaluation (the comparative analysis of
alternative interventions in terms of both costs and consequences) of anti-osteoporosis drugs. Non-original articles
(e.g., editorials, reviews, conference proceedings), partial
economic evaluations, and non-specific drug studies (e.g.,
only use vitamin D and/or calcium as interventions, studies regarding screening strategies, intervention thresholds,
medication adherence, nutrition, model of care, fracture
liaison services, and lifestyle) were excluded.
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2.3 Data Extraction and Quality Assessment
A standardized data-extraction form was developed to collect data from eligible studies. Study characteristics regarding publication (author, year of publication, journal), study
design (country, population, perspective, model type, outcome measure, time horizon, comparators, intervention
duration, cost type, discount rates, year of valuation), study
outcomes (results and sensitivity analysis), and funding
source were extracted by one reviewer (NL) and checked by
another reviewer (DC, LS, DP, SS, RB, or IK). Incremental cost-effectiveness ratios (ICERs) were reported as provided in the articles. Afterwards, for comparability reasons,
all ICERs were converted into 2019 US dollars using the
Organisation for Economic Cooperation and Development
exchange rate and inflation rate [9]. We then synthetized and
analyzed ICERs of active agents compared to traditional oral
bisphosphonates (first-line treatments in most countries),
and of sequential therapies (e.g., abaloparatide/teriparatide
followed by alendronate) by using US$100,000 per qualityadjusted life-year (QALY) gained as the willingness-to-pay
(WTP) threshold. Other information such as country, treatment duration, and annual drug cost was also extracted. In
addition, we checked included studies, especially one-way
sensitivity analyses, to identify key drivers of cost effectiveness; these were eventually chosen through team discussion.
The conduct and reporting quality of included articles
were then appraised using the ESCEO-IOF guideline for
economic evaluations in osteoporosis by two independent
reviewers (NL with DC, LS, DP, SS, RB, or IK). The whole
assessment consisted of two parts. Part one included recommendations for the design and conduct of an economic evaluation in osteoporosis; 29 recommendations were addressed
in nine categories (type of economic evaluation, method for
the conduct of economic evaluation, modeling technique,
base-case analysis and population, mortality, fracture costs
and utility, treatment characteristics, sensitivity analyses,
and outcomes). Part two was an osteoporosis-specific checklist with nine recommendations for reporting, including the
reporting and justification of key modeling aspects (choice
of model, transition probabilities, effect of fracture on costs,
mortality, and utility) and key treatment characteristics (the
effect of treatment per fracture site, the effect of treatment
after discontinuation, the inclusion and approach used to
model medication adherence, therapy costs, and side effects)
[7].
Each recommendation of these two parts was scored
using ‘Yes’ (fulfilled the requirement of reporting), ‘No’
(did not fulfill the requirement), ‘Part’ (partially fulfilled the
requirement), or ‘Not Applicable’ according to the operationalization of the guideline (Appendix 2 in the ESM). To
estimate a score for reporting, we assigned a score of 1 for
‘Yes’, 0.5 for ‘Part’, and 0 for ‘No’. Discrepancies in rating
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were resolved by consensus and consultation with a third
reviewer (MH). It is worth noting that in the scoring system we excluded recommendations that were not directly
connected to the quality level of studies (i.e., ‘use ICUROS
data’, ‘use FRAX® or GARVAN® tools’, ‘consider sequential
therapy as intervention’, and ‘in the absence of hip/wrist
specific efficacy data, use non-vertebral or clinical fracture
efficacy data as replacement’).

reviewed all titles and abstracts of the remaining 3240 studies and subsequently excluded 3188 articles that did not meet
our inclusion criteria. Upon review of the full text of the
remaining 52 studies, 25 articles were excluded for reasons
such as being non-original articles (n = 2), partial-economic
evaluations (n = 4), reporting on non-specific drugs (n = 13),
and studies included in previous review (n = 6). A total of 27
articles were included in our study for data extraction and
quality assessment.

3 Results

3.2 Overview of Included Studies

3.1 Results of Study Selection

The characteristics of included studies are reported in
Table 1. These studies were conducted in 15 different countries. The USA accounted for the largest number (n = 7);
12 studies were conducted in Asia, i.e., three each in Japan
(n = 3), China (n = 3), and Iran (n = 3). Five studies were

Idenficaon

Figure 1 shows the PRISMA flowchart for the identification
of studies. The database search retrieved 3860 records, of
which 620 were found to be duplicates and removed. We

Records identified through database searching
(n =3860)
PubMed:1893
Embase:1898
CEA registry:44 NHS EED:25

Included

Eligibility

Screening

Records after duplicates removed
(n =3240)

Abstract and title screened
(n = 3240)

Full-text articles assessed for
eligibility
(n =52)

Records excluded
(n =3188)

Full-text articles excluded,
with reasons
(n =25)
Non-original articles:2
Partial-economic evaluations:4
Non-specific drugs:13
Articles included in previous
systematic review:6

Studies included in
qualitative synthesis
(n = 27)

Fig. 1  Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of study selection. CEA cost-effectiveness
analysis, NHS EED National Health Service Economic Evaluation database
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Journal of
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Healthcare
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model

Markov cohort
model
No
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model

Markov microsimulation
model

Markov cohort
model
No

Markov cohort
model
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Healthcare

No

Model type

Healthcare

Study
perspectivea

USA

Active drug(s) vs no treatment/calcium + vitamin D
Golmohamdi
Electronic Physi- Iran
et al. [12]
cian
Kwon et al.
Journal of Bone Korea
[32]
Metabolism

References

Lifetime

Lifetime

12 months

Lifetime

Average percent- 12 months
age of change
in BMD

QALY

QALY

All costs are
compared

QALY

Lifetime

Lifetime

QALY

QALY

0–15 years

Lifetime

12 and
36 months
Lifetime

Time horizon

Fracture events

QALY

QALY

BMD

Outcome measure

Table 1  Characteristics of published articles assessing the cost effectiveness of drugs for osteoporosis

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Cost type

NR

3%, 3%

3%, 3%

NR

3%, 3%

7.2%, 5%

3%, 3%

NR

3%, 3%

5%, 5%

NR

Discount rates
(costs, QALY)

NR

Amgen SA Barcelona, Spain, and
GSK

Amgen Inc

NR

NR

China Postdoctoral
Science Foundation Grant,
NSFC, Beijing
Natural Science
Foundation
CinnaGen Corporation

NR

Takeda Pharmaceutical Company Limited,
Korea
NR

NR

Funding source
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Journal

Country

Osteoporosis
International

Moriwaki et al.
[30]

O’Hanlon et al. Clinical Thera[35]
peutics
Yoshizawa
Archives of
et al. [29]
Osteoporosis
Journal of
Chokchalerthe Medical
mwong et al.
Association of
[23]
Thailand
Coyle et al. [24] Medical Decision Making
Policy &
Practice

Osteoporosis
International

Cost Effectiveness and
Resource
Allocation
Medical journal
of the Islamic
Republic of
Iran
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International

Mori et al. [19]

Mori et al. [18]

Azar et al. [13]

Karnon et al.
[14]

Healthcare
Societal
Societal

Healthcare

Japan
Thailand

Canada

Healthcare

USA

Japan

USA

Healthcare,
societal and
governmental
Societal

Healthcare

Iran

Japan

Healthcare

Healthcare

Healthcare

Study
perspectivea

Australia

Silverman et al. Journal of Osteo- USA
[22]
porosis
China
Chen et al. [31] Patient Preference and
Adherence
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Table 1  (continued)

Markov cohort
model

QALY

Lifetime

Lifetime

QALY
QALY

Lifetime

QALY

1.5 years; Lifetime
Lifetime

Lifetime

QALY

QALY

Lifetime

QALY

Markov microsimulation
model
Markov microsimulation
model
Markov microsimulation
model
Markov cohort
model
Markov cohort
model
Markov microsimulation
model

2 years

QALY

10 years

Lifetime

QALY

QALY

Lifetime

Time horizon

QALY

Outcome measure

Decision tree
model

Markov cohort
model

Markov cohort
model
Markov microsimulation
model

Model type

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct costs

Direct and indirect costs

Direct costs

Direct costs

Direct costs

Direct costs

Cost type

1.5%, 1.5%

3%, 3%

3%, 3%

3%, 3%

2%, 2%

3%, 3%

3%, 3%

3%, 3%

5%, 5%

3%, 3%

3%, 3%

Discount rates
(costs, QALY)

NR

NR

NR

Veterans Affairs
Special
Fellowship in
Advanced Geriatrics
Asahi Kasei
Pharma Corporation
NR

NR

NR

NSFC and Jiangsu
Research on
Philosophy and
Social Science
in University
of Education
Department of
Jiangsu Province
No funding

Amgen Inc

Funding source
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Osteoporosis
International

Journal

JBMR PLUS

Healthcare
Healthcare

USA
USA
Healthcare and
societal

Healthcare

China

USA

Healthcare

Study
perspectivea

France

Country

Markov microsimulation
model
Discrete-event
simulation
model
Markov microsimulation
model

Markov microsimulation
model
Markov cohort
model

Model type

40 years

Lifetime
10 years
Lifetime

QALY
QALY
QALY

Lifetime

QALY
QALY

Time horizon

Outcome measure

a

As stated by the authors

BMD bone mineral density, NR not reported, NSFC National Natural Science Foundation of China, QALY quality-adjusted life-year

Mori et al. [20]

The Journal
of the North
American
Menopause
Society
Sequential therapies
Hiligsmann
Seminars in
et al. [28]
Arthritis and
Rheumatism
Le et al. [16]
Annals of Pharmacotherapy

Li et al. [15]

Hiligsmann
et al. [27]
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Table 1  (continued)

Direct and indirect costs

Direct costs

Direct costs

Direct and indirect costs

Direct costs

Cost type

3%, 3%

3%, 3%

3%, 3%

3%, 3%

3%, 3%

Discount rates
(costs, QALY)

JMDC Inc., SMS
CO. and LTD

Radius Health,
Inc., Waltham
MA
Radius Health, Inc

NSFC, Science
and Technology
Department of
Fujian Province
of China

Teva and Theramex

Funding source
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performed in five different European countries. Twelve of
the 27 studies were published in osteoporosis journals, particularly in Osteoporosis International (n = 5).
Most studies used the healthcare perspective (n = 21),
some with a societal perspective (n = 4), while one study
used both societal and healthcare perspectives, and another
study reported societal, healthcare, and governmental perspectives. All studies included direct costs and only three
also considered indirect costs [15, 18, 20]. However, we
found that some studies including both direct and indirect
costs were not defined as having a societal perspective,
although this was the original information stated by authors
reported in Table 1; no adjustment and correction were
made for this. Nineteen studies applied a lifetime horizon
while others considered truncated time horizons [10–15].
A Markov model was used in 21 studies, consisting of a
Markov cohort model (n = 12) or a Markov microsimulation
model (n = 9). One study applied a discrete-event simulation model [16], another a decision-tree model [13]. Qualityadjusted life-years (QALYs) were used as the outcome in
these 23 studies with a model. The remaining four studies
used no model [10–12, 17]. One out of the four conducted
a cost-minimization analysis [10], in which costs were
compared. Another two studies [11, 12] used bone mineral
density (BMD) as the final outcome and ICER was calculated based on the differences of costs and BMD of different
interventions. Furthermore, the number of fracture events
was regarded as the outcome in the fourth study [17], ICER
was calculated based on the differences of average annual
costs divided by the difference of numbers of hip fractures
prevented between bisphosphonates and the combination of
calcium and vitamin D. Fourteen studies were funded by
pharmaceutical companies or national public funds, while
13 studies did not mention the source of funding or had no
funding.
Table 2 presents characteristics of the studied population, the active intervention and comparator, year of costing
valuation, sensitivity analysis, and the main results of the
articles. Study populations differed between studies in BMD
T-score, mean age, history of fracture, or even tolerance of
oral bisphosphonates. Some studies included patients stratified for age and two studies included only a male population
[21, 22].
Twelve active drugs were assessed in the studies, including various pharmacological treatments such as bisphosphonates (alendronate, etidronate, risedronate, ibandronate, and
zoledronic acid), raloxifene, strontium ranelate, denosumab,
and teriparatide, and including new agents such as abaloparatide, romosozumab, and gastro-resistant risedronate.
Twelve studies included two or more active drugs in their
analysis [13, 15–17, 21–28]. Oral bisphosphonates were
included in 11 studies [13–15, 18, 21, 22, 24–26, 29, 30]
and compared with other active interventions. There were
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three studies [16, 20, 28] considering sequential therapies as
comparators, while six studies [15, 17, 30–32, 36] made the
comparison between active osteoporotic drugs and calcium/
vitamin D3 and ten studies [12, 18, 19, 23–25, 27–29, 33, 34]
included no treatment as the comparator. Treatment duration
in most studies was similar to randomized controlled trials,
indications, or guidelines (e.g., 3 or 5 years for anti-resoptive
agents, 12–24 months for anabolic agents). Both a deterministic sensitivity analysis (e.g., one-way, multivariate)
and a probabilistic sensitivity analysis were conducted in
17 studies. Two studies [24, 26] applied only a probabilistic
sensitivity analysis and three studies applied only a one-way
sensitivity analysis [13, 32, 34]. Sensitivity analysis was not
conducted in five studies [10–12, 17, 35]. We presented the
WTP threshold in Table 2 as stated by the authors and no
adjustment was made. The WTP threshold was shown to be
different even through studies had been conducted in the
context of the same country.
Table 3 summarizes the results of the cost-effectiveness
analysis between traditional oral bisphosphonates and other
active drugs in 2019 US dollars. Annual drug costs for
branded oral bisphosphonates had a range from US$123
to US$1874; the cost for generic oral bisphosphonates was
much lower, from US$7 to US$458. The annual cost of denosumab differed steeply between countries, from US$608
to US$1811. Several studies made comparisons between
denosumab and oral bisphosphonates.
Specifically, eight studies [14, 18, 21, 22, 24–26, 29]
made comparisons between denosumab and oral alendronate, of which five studies [18, 22, 25, 26, 29] demonstrated that denosumab was cost effective, and one study
[21] showed that denosumab was a dominant option if we
applied US$100,000 per QALY gained as the WTP threshold. In addition, when compared with risedronate and ibandronate, denosumab was also shown to be cost effective [25,
26] or dominant [21, 22]. However, two studies [14, 24]
showed that denosumab was not cost effective with large
ICERs when compared with alendronate; this was caused
by minimal incremental QALYs. In addition, comparisons
between oral and non-oral bisphosphonates were performed
in some studies. Three studies [15, 20, 24] were conducted
between zoledronic acid and oral alendronate, with one
study indicating that zoledronic acid was dominant [15]; in
the other two studies, zoledronic acid was not cost effective or was dominated by alendronate [20, 24]. As a new
formulation of bisphosphonates, gastro-resistant risedronate
was cost effective in comparison with alendronate and risedronate in one study [27]. Furthermore, another study compared teriparatide with risedronate, showing that teriparatide
was not cost effective. Overall, 67% studies (eight of a total
12 studies) or 82% of comparisons (23 of a total 28 studies)
suggested that active interventions (denosumab, zoledronic
acid, gastro-resistant risedronate, or teriparatide) were cost

Population (base case)

Postmenopausal women aged
55, 60, or 65 years with BMD
T-scores from − 2.0 to − 2.4 at
the femoral neck, and without
previous osteoporotic fractures

Women aged 85 years with BMD
T-score ≤ − 2.0 at the spine, hip,
or radius who resided in nursing
homes

Kwon et al. [32]

Ito et al. [36]

Active drug(s) vs no treatment/calcium + vitamin D
Golmohamdi et al. [12]
Postmenopausal women with
osteoporosis

References

No

One-way

One-way probabilistic

2014

2017

Calcium/ vitamin D vs (raloxifene + calcium/ vitamin D) or
(risedronate + calcium/vitamin
D)

(Zoledronic acid + calcium/vitamin D) vs usual care (calcium/
vitamin D)

Sensitivity analysis

2013

Year of
costing
valuation

Zoledronic acid vs placebo

Comparators

Table 2  Results of cost-effectiveness analyses of drugs for osteoporosis

One percent increase of BMD on
femoral neck, hip trochanter,
total hip, and lumbar spine
requires further cost of US$386,
US$264, US$388, and US$347,
respectively. Zoledronic acid is a
cheaper and better approach and
can be considered as a dominant
approach
In comparison with calcium/vitamin D supplements, drug therapy
(raloxifene or risedronate + calcium/vitamin D) had an ICER
of US$16,472 and US$6741 per
QALY gained for treatment started
at the age of 55 and 60 years,
respectively. Given the WTP
threshold (US$25,700), pharmaceutical treatment was cost
effective. For older women starting medication at 65 years of age,
pharmaceutical intervention was a
dominant strategy
In comparison with usual care,
zoledronic acid had an ICER of
US$207,400 per QALY gained.
Given the WTP threshold
(US$100,000), zoledronic acid
was not cost effective

Results
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Zoledronic acid vs no treatment

Postmenopausal osteoporotic
women

Cui et al. [34]

Comparators

Oral bisphosphonates (alenAdult patients diagnosed with
dronate, risedronate or ibanosteoporosis related to glucocordronate) vs calcium/vitamin D
ticoid drugs use

Population (base case)

Mohd-Tahir et al. [17]

References

Table 2  (continued)

One-way

No

2014

2019

Sensitivity analysis

Year of
costing
valuation

Overall, in comparison with calcium/vitamin D, the use of bisphosphonates could not be considered
cost effective for treatment of all
patients with GIO. Bisphosphonates were considered cost effective if started in patients more than
60 years old. However, bisphosphonates were not cost effective
in patients with GIOP secondary osteoporosis. The ICERs of
bisphosphonates in patients with
previous fracture or with rheumatoid arthritis were estimated at
MYR 108,603 and MYR 25,699
per QALY gained, respectively.
Given the WTP threshold (MYR
26,317), bisphosphonates were
cost effective in patients with
rheumatoid arthritis
In comparison with no treatment,
zoledronic acid had ICERs
of US$26,637, US$22,129,
US$20,338, US$19,285,
US$18,181, US$16,680,
US$15,047, and US$14,447 per
QALY at FRAX threshold 0.02,
0.06, 0.07,0.08, 0.09, 0.1, 0.5,
and 1, respectively. Zoledronic
acid was cost effective when
the 10-year probability of major
osteoporotic fracture based on
FRAX was above 7%
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Women aged 70 years, BMD
T-score − 2.5 with previous
fracture or BMD T-score -3.0
without prior fracture

Population (base case)

Postmenopausal women aged
45–79 years with low BMD
in the lumbar spine and/or
right hip, a Karnofsky index of
90–100

Postmenopausal women
aged 65 years with a BMD
T-score < − 4 SD

Venice et al. [10]

Waure et al. [26]

Active drug(s) versus active drug(s)
Parthan et al. [21]
Men aged 75 years and older with
osteoporosis

Taheri et al. [33]

References

Table 2  (continued)

No

Probabilistic

2010

2009

Alendronate vs zoledronic acid

Denosumab vs (risedronate,
generic and branded alendronate, ibandronate, and
strontium ranelate)

One-way probabilistic

One-way probabilistic

2018

Teriparatide vs no treatment

Sensitivity analysis

2012
Denosumab vs (generic alendronate, strontium ranelate, zoledronic acid, generic risedronate,
ibandronate, and teriparatide)

Year of
costing
valuation

Comparators

Total lifetime costs for denosumab,
generic alendronate, strontium
ranelate, zoledronic acid, generic
risedronate, ibandronate, and teriparatide were €31,004, €33,731,
€34,788, €34,796, €34,826,
€35,983, and €37,461, respectively. Total QALYs were 5.23,
5.15, 5.15, 5.17, 5.13, 5.12, and
5.22, respectively In comparison
with other treatments, denosumab
had the lowest costs and highest
QALYs. Denosumab dominated
all comparators
Compared with oral alendronate,
zoledronic acid provided an
annual savings of 15% of the
direct costs for 1 year. Zoledronic
acid infusion is also linked to
a higher increase in BMD and
compliance
The ICERs for denosumab, in
comparison with risedronate,
generic alendronate, branded
alendronate, ibandronate, and
strontium ranelate were estimated
at €10,302, €18,047, €17,133,
€2158, and €69 per QALY gained,
respectively. Given the WTP
threshold (€30,000), denosumab is
cost effective

In comparison with no treatment,
teriparatide was indicated to be
more costly and associated with
fewer fractures, more life-years,
and more QALYs, with an ICER
of IRR 254,750,619 per QALY
gained. It could be considered as a
cost-effective treatment in severe
PMO at the WHO recommended
threshold
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Postmenopausal women
aged 65 years with BMD
T-score ≤ -2.5 at the femoral
neck and without previous fractures (initial population)

Patented denosumab vs generic
Women with a mean age of
alendronate
72 years (range 60–90 years)
with a mean BMD T-score at the
femoral neck of − 2.15, and with
24% of women having experienced a previous fracture

Chen et al. [31]

Karnon et al. [14]

Raloxifene vs conventional treatment (calcitonin or alendronate
or calcium/vitamin D)

Men with a mean age of 78 years Denosumab vs (generic alendronate, risedronate, ibanwith BMD T-score of − 2.12 and
dronate, teriparatide, and
a vertebral fracture prevalence
zoledronic acid)
of 23%

Silverman et al. [22]

Deterministic probabilistic

One-way probabilistic

2015

2012

One-way probabilistic

2013

NR

No

Menopausal or postmenopausal
women aged 50 years with
T-score − 1 to -6, diagnosed for
the first time

Miraci et al. [11]

Ibandronate vs alendronate

Sensitivity analysis

Probabilistic, multivariate, univariate

Year of
costing
valuation

Denosumab vs (alendronate, iban- 2013
dronate, risedronate, strontium
ranelate, and no treatment)

Comparators

Postmenopausal women
age 65 years with BMD
T-score ≤ 2.5 or less

Population (base case)

Darbà et al. [25]

References

Table 2  (continued)

The ICER for denosumab compared
with no treatment, alendronate,
risedronate, and ibandronate were
estimated at €6823, €16,294,
€4895, and €2205 per QALY
gained, respectively. Given
the WTP threshold (€20,000),
denosumab is cost effective.
Denosumab is a dominant treatment option in comparison with
strontium ranelate
The cost/efficacy ratio (1% change
of BMD) was 13.434 units for
ibandronate and 31.677 units for
alendronate type A1. Ibandronate
is more effective and cost effective
than alendronate in the treatment
of osteoporosis
Compared with generic alendronate,
denosumab had an ICER of
US $16,888 per QALY gained.
Given the WTP threshold (US
$100,000), denosumab is cost
effective. Compared with risedronate, ibandronate, teriparatide,
and zoledronic acid, denosumab is
a dominant option
Compared with conventional treatment, treatment with raloxifene
had an ICER of US$36,891 per
QALY gained. Given the WTP
threshold of US$20,000), raloxifene was not cost effective
Compared with alendronate,
denosumab had an ICER of
AUD$246,749 per QALY
gained. Given the WTP threshold
(AUD$100,000), denosumab is
not cost effective
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One-way probabilistic

2014

Oral bisphosphonate vs no treatment, combined strategy (bisphosphonate + falls prevention
exercise) and (falls prevention
exercise only)

Mori et al. [19]

Community-dwelling non-Hispanic white women at different
starting ages (65, 70, 75, and
80 years) and without previous
hip, vertebral, or wrist fractures

One-way probabilistic

2016

Alendronate vs denosumab vs no
Postmenopausal osteoporotic
treatment
women without previous hip or
vertebral fractures at various
ages of therapy initiation (65, 70,
75, and 80 years)

Mori et al. [18]

One-way

2014

Sensitivity analysis

Risedronate vs (alendronate and
teriparatide)

Year of
costing
valuation

Comparators

Postmenopausal women aged
over 60 years with BMD
T-score ≤ 2.5 and with at least
a previous spine, wrist, or hip
fracture caused by osteoporosis

Population (base case)

Azar et al. [13]

References

Table 2  (continued)

Compared with risedronate,
alendronate and teriparatide
had ICERs of US$-2178 and
US$483,783 per QALY gained.
Given the WTP threshold
(US$14,010), alendronate is
the dominant and cost-effective
treatment option. The treatment
strategy of teriparatide is more
expensive than risedronate and
alendronate and is associated with
very little increase in QALYs
For patients aged 75 and 80 years,
denosumab was cost saving from
any of the three perspectives, in
comparison with alendronate For
patients aged 65 and 70 years,
denosumab had an ICER of
US$25,700 and US$5000 per
QALY gained, from a societal
perspective, and did not exceed
a WTP threshold (US$50,000).
Therefore, denosumab was a costeffective option
Compared with an oral bisphosphonate alone, the combined strategy
had ICERs of US$202,020,
US$118,460, US$46,870, and
US$17,640 per QALY for patients
aged 65, 70, 75, and 80 years,
respectively. Given the WTP
threshold (US $100,000), the combined strategy for patients ages 75
and 80 years was cost effective.
The combined strategy provided
better health at lower cost than the
falls prevention exercise alone at
ages 70, 75, and 80 years
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Women of 70 years with BMD
T-scores < − 2.5 and a previous
vertebral fracture

Women aged 75 years with BMD
T-score − 2.87 and with a previous vertebral body fracture

O’Hanlon et al. [35]

Yoshizawa et al. [29]

Chokchalermwong et al. [23] Postmenopausal women
aged ≥ 50 years with osteoporosis and without previous
fractures

Women of 70 years with BMD
T-score of − 2.5 and a previous
vertebral fracture

Population (base case)

Moriwaki et al. [30]

References

Table 2  (continued)

No

2016

2016

Alternative bone-forming agent
profiles vs the teriparatide
reference case; alternative
bone-forming agent profiles vs
(sequential teriparatide + denosumab)

Denosumab vs alendronate; alendronate vs no treatment

(Oral bisphosphonates, raloxifene, 2015
strontium ranelate, and denosumab) vs no treatment

Deterministic
probabilistic

2016

Alendronate + basic treatment
(placebo + calcium + vitamin D)
vs basic treatment; (zoledronic
acid + basic treatment) vs (alendronate + basic treatment)

One-way probabilistic

Deterministic probabilistic

Sensitivity analysis

Year of
costing
valuation

Comparators

For patients 70 years of age,
zoledronic acid was dominated by
alendronate. However, the incremental QALY is quite small in
extent. Considering the advantage
of annual zoledronic acid treatment in compliance and persistence, zoledronic acid may be a
cost-effective treatment option
compared to alendronate
In comparison with teriparatide,
alternative bone-forming agent
profiles produced a net monetary
benefit of US$17,000,000 per
10,000 treated patients during the
1.5 years and US$80,000,000 over
a lifetime horizon that included
3.5 years of maintenance treatment with denosumab
Compared with alendronate, denosumab had an ICER of US$40,241
per QALY gained. Assuming a
WTP threshold (US$50,000),
denosumab was cost effective
In comparison with no treatment,
none of the alternative drugs were
cost effective at baseline case. For
women from the age of 65 years,
with a BMD T-score ≤ -2.5, oral
bisphosphonates were the only
drugs cost effective (the ICER
was THB130,049), followed by
denosumab and raloxifene, respectively. Strontium ranelate was
dominated by no treatment
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Women aged 70–74 years with
osteoporosis and without previous fractures who are able to
tolerate oral bisphosphonates

Postmenopausal women aged
60–80 years with BMD
T-score ≤ -2.5 and/or prevalent
vertebral fractures

Hiligsmann et al. [27]

Population (base case)

Coyle et al. [24]

References

Table 2  (continued)

One-way probabilistic

2017
Gastro-resistant risedronate vs
(generic risedronate, alendronate
and no treatment)

Sensitivity analysis

Probabilistic

Year of
costing
valuation

2017
Alendronate vs etidronate vs
risedronate vs zoledronic acid vs
denosumab vs no treatment

Comparators

For patients who can tolerate oral
bisphosphonates, in comparison
with no treatment, alendronate,
risedronate, zoledronic acid,
and denosumab had ICERs
of CAN$3751, CAN$85,557,
CAN$83,503, and CAN$238,523
per QALY gained, respectively.
Given the WTP threshold
(CAN$50,000), alendronate was
the only cost-effective drug. In
comparison with alendronate,
risedronate and etidronate were
dominated, and zoledronic acid
and denosumab were associated
with a high ICER. For patients
who are unable to tolerate oral
bisphosphonates, dependent on
age and fracture history, compared
with no treatment, the ICER for
zoledronic acid had a range from
CAN$17,770 to CAN$94,365
per QALY. Denosumab was
dominated by zoledronate or had
an ICER greater than CAN$3.0
million
The ICER for GR risedronate, compared with alendronate, generic
risedronate and no treatment,
ranged from €2037 to €21,875
per QALY gained. Given the
WTP threshold (€60,000), GR
risedronate was cost effective In
women aged 75 years and older,
GR risedronate was even shown to
be dominant
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Sequential therapies
Hiligsmann et al. [28]

Li et al. [15]

References

Table 2  (continued)
Year of
costing
valuation

2017

2018
(Alendronate, zoledronic acid,
raloxifene and teriparatide) vs
calcium/vitamin D; (alendronate,
raloxifene and teriparatide) vs
zoledronic acid

Comparators

(Sequential abaloparatide + alenWomen aged 50–80 years with a
dronate) vs (sequential teriBMD T-score ≤ -3.5 and without
paratide + alendronate) and no
fracture history or with a BMD
treatment
T-score − 2.5 to − 3.5 and a history of at least one osteoporotic
fracture

Women aged over 60 years with
BMD T-score ≤ 2.5 in the lumbar spine or femoral neck and
without previous fractures

Population (base case)

One-way probabilistic

Univariate probabilistic

Sensitivity analysis

In comparison with sequential
TPTD/ALN therapy, sequential
ABL/ALN therapy was dominant
in all simulated populations. Compared with no treatment, in women
with BMD T-score ≤ 3.5 (age over
70 years), the sequential ABL/
ALN therapy was cost saving; and
in women with a BMD T-score
-2.5 to -3.5 and history of one
osteoporotic fracture, the ICER
was estimated at US$125,493,
US$91,394, US$81,865,
US$51,906, US$38,763,
US$31,390, and US$28,086 for
patients aged 50 years, 55 years,
60 years, 65 years, 70 years,
75 years, and 80 years, respectively. Given the WTP threshold
(US$100,000), sequential ABL/
ALN therapy was cost effective for
patients aged over 55 years

Compared with calcium/vitamin D, zoledronic acid had an
ICER of US$7864 per QALY
gained. Given the WTP threshold
(US$28,624), zoledronic acid
was cost-effective. The ICER of
teriparatide versus zoledronic
acid was US$470,797 per
QALY gained, which exceeded
the threshold. Alendronate and
raloxifene were dominated by
zoledronic acid
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One-way probabilistic

One-way probabilistic

2017

2018

Sensitivity analysis

Year of
costing
valuation

Compared with TPTD/ALN over a
10-year time horizon, ABL/ALN
was dominant. In comparison with
PBO/ALN, ABL/ALN had an
ICER of US$333,266 per QALY
gained. In high-risk women, ABL/
ALN was also cost effective in
comparison with TPTD/ALN, and
had an ICER of US$188,891 per
QALY gained relative to PBO/
ALN
Compared with alendronate alone
from the societal perspective,
sequential teriparatide/alendronate
had an ICER of US$434,400,
US$330,000, US$280,100, and
US$290,800 per QALY for
women aged 65, 70, 75, and
80 years, respectively. From a
healthcare perspective, the ICERs
were US$441,700, US$336,700,
US$288,200, and US$299,100 per
QALY, respectively, Given the
WTP threshold (US$150,000),
sequential teriparatide/alendronate
was not cost effective unless the
costs of generic/biosimilar teriparatide were heavily discounted
with respect to the current brand
cost

Results

ABL abaloparatide, ALN alendronate, AUD Australian Dollar, BMD bone mineral density, GIOP glucocorticoid-induced osteoporosis, GR gastro-resistant, ICER incremental cost-effectiveness
ratio, IRR Iranian Rial, NR not reported, PBO placebo, PMO postmenopausal osteoporosis, PTH parathyroid hormone, QALY quality-adjusted life-year, MYR Malaysian Ringgit, THB Thai Baht,
TPTD teriparatide, WTP willingness to pay, WHO World Health Organization

(Sequential teriparatide + alenCommunity-dwelling white
osteoporotic women aged 65, 70, dronate) vs alendronate alone
75, and 80 years with previous
vertebral fracture

Mori et al. [20]

(Sequential abaloparatide + alendronate) vs (sequential
teriparatide + alendronate) and
(placebo + alendronate)

Comparators

Postmenopausal women aged
68.8 years with osteoporosis

Population (base case)

Le et al. [16]
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Table 3  Cost-effective analyses between oral bisphosphonates and other active drugs for osteoporosis
References

Country

Intervention and comparator

Treatment
duration
(years)

Annual drug costs
(intervention/comparator)

ICER

Coyle et al. [24]
Darbà et al. [25]
Waure et al. [26]

Canada
Spain
Italy

Karnon et al. [14]
Mori et al. [18]

Australia
Japan

2
5
4
4
5
5

US$663/US$123
US$608/US$237
US$842/US$458
US$842/US$502–528
US$624/US$230
US$799/US$246

Parthan et al. [21]
Silverman et al. [22]
Yoshizawa et al. [29]
Darbà et al. [25]
Waure et al. [26]
Parthan et al. [21]
Silverman et al. [22]
Darbà et al. [25]
Waure et al. [26]
Parthan et al. [21]
Silverman et al. [22]
Coyle et al. [24]
Li et al. [15]
Moriwaki et al. [30]
Hiligsmann et al. [27]
Azar et al. [13]
Hiligsmann et al. [27]

Sweden
USA
Japan
Spain
Italy
Sweden
USA
Spain
Italy
Sweden
USA
Canada
China
Japan
France
Iran
France

Denosumab vs alendronate
Denosumab vs alendronate
Denosumab vs generic alendronate
Denosumab vs branded alendronate
Patented denosumab vs generic alendronate
Denosumab vs alendronate (SP, 65 years)
Denosumab vs alendronate (SP, 70 years)
Denosumab vs alendronate (HP, 65 years)
Denosumab vs alendronate (HP, 70 years)
Denosumab vs alendronate (GP, 65 years)
Denosumab vs alendronate (GP, 70 years)
Denosumab vs generic alendronate
Denosumab vs generic alendronate
Denosumab vs alendronate
Denosumab vs risedronate
Denosumab vs risedronate
Denosumab vs generic risedronate
Denosumab vs risedronate
Denosumab vs ibandronate
Denosumab vs ibandronate
Denosumab vs ibandronate
Denosumab vs ibandronate
Zoledronic acid vs alendronate
Zoledronic acid vs alendronate
Zoledronic acid vs alendronate
GR risedronate vs alendronate
Teriparatide vs generic risedronate
GR risedronate vs generic risedronate

5
5
5
5
4
5
5
5
4
5
5
2
3/5
3
3
2
3

US$733/US$49
US$1811/US$33
US$743/US$289
US$608/US$414
US$842/US$455
US$733/US$64
US$1811/US$1874
US$608/US$227
US$842/US$819
US$733/US$544
US$1811/US$1462
US$298/US$123
US$536/US$555
US$350/US$273
US$58/US$55
US$1757/US$7
US$58/US$37

US$2,376,812
US$23,746
US$29,980
US$28,462
US$284,397
US$27,375
US$5326
US$32,061
US$7137
US$28,546
US$6178
Dominant
US$18,532
US$40,969
US$7134
US$17,114
Dominant
Dominant
US$3213
US$3585
Dominant
Dominant
US$535,359
Dominant
Dominant
US$2401
US$522,424
US$2759

GP governmental perspective, GR gastro-resistant, HP healthcare perspective, ICER incremental cost-effectiveness ratio, SP societal perspective

effective when compared with traditional oral bisphosphonates. Additionally, comparisons between active interventions were also made in some studies; two studies showed
that denosumab was cost effective [26] or dominant [21]
when compared with strontium ranelate. Zoledronate acid
and teriparatide were dominated by denosumab in another
two studies [21, 22].
Table 4 presents three studies [16, 20, 28] that estimated
the cost effectiveness of sequential therapies from the US
perspective. Hiligsmann et al. [28] analyzed populations
with different BMD T-scores at baseline, and the study of
Mori et al. [20] assessed women at different ages and from
both healthcare and societal perspectives. Hiligsmann et al.
[28] and Le et al. [16] assessed sequential therapies starting with 1.5 years of abaloparatide or teriparatide, followed
by 5 years of alendronate as the treatment duration. In the
study of Mori et al. [20], 2 years of initial treatment with

teriparatide was followed by 10 years of alendronate. The
monthly drug costs for abaloparatide were similar between
studies, at approximately US$1700; the cost of teriparatide
was from US$1711 to US$3722 per month. Abaloparatide
followed by alendronate was shown to be dominant when
compared with teriparatide followed by alendronate in two
studies [16, 28]. In addition, when compared with a placebo or no treatment, Hiligsmann et al. [28] showed that
abaloparatide followed by alendronate was cost saving or
cost effective in different populations. In the study of Le
et al. abaloparatide or teriparatide followed by alendronate
was not cost effective when compared with a placebo followed by alendronate [16]. Furthermore, Mori et al. [20]
compared sequential therapy (teriparatide followed by alendronate) with alendronate alone at different ages and economic perspectives, indicating that sequential therapy was
not cost effective. The high drug costs of abaloparatide and
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Table 4  Cost-effective analyses of sequential therapy
References

Country Population

Hiligsmann et al. [28] USA

Le et al. [16]

USA

Hiligsmann et al. [28] USA

Le et al. [16]

Mori et al. [20]

USA

USA

BMD T-score ≤ − 3.5, age 70 or
− 3.5 ≤ BMD T-score ≤ − 2.5 and
history of one osteoporotic fracture, age 70 y
Aged ≥ 65 y with a prior vertebral
fracture
BMD T-score ≤ − 3.5, age 70 y
− 3.5 ≤ BMD T-score ≤ − 2.5 and
history of one osteoporotic fracture, age 70 y
Aged ≥ 65 y with a prior vertebral
fracture

Age 65 y (SP)
Age 70 y (SP)
Age 75 y (SP)
Age 80 y (SP)
Age 65 y (HP)
Age 70 y (HP)
Age 75 y (HP)
Age 80 y (HP)

Comparator (treatment duration)

Monthly drug costs ICER

Sequential ABL(1.5y)/ALN(5y) vs
sequential TPTD(1.5)/ALN(5y)

ABL US$1695
TPTD US$3387
ALN US$10

Dominant

Sequential ABL(1.5y)/ALN(5y) vs
sequential TPTD(1.5)/ALN(5y)

ABL US$1795
TPTD US$3722
ALN US$10
ABL US$1695
ALN US$10

Dominant

Sequential ABL(1.5y)/ALN(5y) vs
no treatment

Sequential ABL(1.5y)/ALN(5y) vs
PBO/ALN(5y)
Sequential TPTD(1.5y)/ALN(5y) vs
PBO/ALN(5y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)
Sequential TPTD(2y)/ALN(10y) vs
ALN(10y)

ABL US$1795
ALN US$10
TPTD US$3722
TPTD US$1711
ALN US$17

Cost saving
US$40,428
US$347,577
US$991,854
US$442,263
US$335,973
US$285,170
US$296,063
US$449,695
US$342,794
US$293,416
US$304,514

ABL abaloparatide, ALN alendronate, BMD bone mineral density, HP healthcare perspective, ICER incremental cost-effectiveness ratio, SP societal perspective, TPTD teriparatide, y years

teriparatide largely affected ICERs when compared with no
treatment, a placebo, and with alendronate alone.

3.3 Critical Appraisal
Table 5 presents the results of the quality assessment of the
design and conduct of economic evaluations in osteoporosis using the ESCEO-IOF guideline. Substantial differences
were observed between studies with an average score of 17
out of 25 (range 2–25). Although some studies followed several recommendations of the guideline, room for improvement was observed for most studies.
Figure 2 shows the percentage of studies that fully,
partially, or did not report the individual recommendations in the guideline. The most frequently unreported
recommendations were ‘an additional effect after multiple
fractures’ (i.e., an additional effect on costs and/or utility should be modeled), ‘adverse events’ (i.e., important

side effects that have an impact on costs and/or utility
need to be included), and ‘proportion attributed to the
fracture’ (i.e., a proportion of excess mortality attributed
to the fracture should be included). In addition, some recommendations such as ‘avoid hierarchy of fractures and
restrictions after fracture events’ (e.g., the absence of a
non-hip fracture after a previous hip fracture or a limit to
the number of fracture events) and ‘multiple scenarios’
(i.e., include age range and fracture risk levels) were frequently partially reported.
The results of reporting quality assessment are presented
in Table 6; most recommendations were well reported with
an average score of 6.8 out of 9 (range 0.5–9). The quality of reporting was suboptimal for ‘treatment side effects’
(i.e., describing the approaches and data sources used for
costs and utilities effects of adverse events). Furthermore,
‘medication adherence’ (i.e., describing approaches and
data sources used for modeling medication adherence) was

Efficacy data from RCTs, (network) meta-analysis

Recommendation

Cost-utility analysis using QALY as outcome
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poorly reported in some articles [10–13, 15, 17, 23, 26, 33],
as well as ‘treatment effect after discontinuation’ in six articles (i.e., these studies did not assume a linear decrease of
the effect after discontinuation for a period similar to the
duration of treatment) [10–13, 23, 24].

3.4 Key Drivers of Cost Effectiveness
Several drivers of cost effectiveness were identified, including baseline fracture risk, drug effect on the risk of fractures,
drug cost, and medication adherence/persistence.
3.4.1 Baseline Fracture Risk
Most studies indicated that the increase of baseline fracture
risk and the age of patients were associated with favorable results of cost-effectiveness analyses of osteoporotic
drugs. For instance, Moriwaki et al. [30] indicated that the
incremental costs and incremental QALYs of zoledronic
acid compared with alendronate tended to be small, with
an increase of T-scores. Moreover, Chokchalermwong et al.
[23] reported that, compared to no treatment, the ICER
of bisphosphonates was 130,049 THB per QALY when
starting the drug from the age of 65 years, with a BMD
T-score ≤ − 2.5. However, denosumab was cost effective
from the age of 80 years and over.
3.4.2 Drug Effect on the Risk of Fractures
Twelve studies [15, 18, 20–23, 25, 29–32, 36] reported that
the cost effectiveness result of osteoporotic drugs is most
sensitive to changes in the effect of osteoporotic drugs on the
risk of fractures. Silverman et al. [22] indicated that when
the relative risk of hip fracture with denosumab is lowered
from 0.38 (baseline) to 0.18, denosumab still dominates
the generic alendronate. However, when this relative risk is
increased to 0.78, denosumab is no longer a cost-effective
option. This finding is similar to the study of Parthan et al.
[21] and Yoshizawa et al. [29]. In addition, Moriwaki et al.
[30] reported that the relative risk of hip fracture with zoledronic acid had a relatively strong effect on the estimated
incremental net monetary benefit; compared to alendronate,
zoledronic acid could be a cost-effective option if the relative risk was equal to 0.34 (lower limit).
3.4.3 Drug Cost
Variation in drug costs could lead to different cost-effectiveness results of anti-osteoporosis drugs. The strong
effect of drug cost was reported in several studies [13, 14,
20, 23, 27–30, 33, 34]. Mori et al. [20] compared sequential therapy (teriparatide followed by alendronate) to alendronate alone and reported that results were most sensitive
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to the changes in the estimated cost of teriparatide. If the
cost of a generic/biosimilar was estimated to be 15% of
the brand (i.e., 85% less), the annual cost of teriparatide
would be $6490 for a 65-year-old cohort; or if the cost of
a generic/biosimilar was estimated to be 35% of the brand
(i.e., 65% less), the annual cost of teriparatide would be
$11,461 for a 75-year-old cohort; the ICERs of sequential
teriparatide/alendronate were below the WTP threshold
of $150,000/QALY. Moriwaki et al. [30] also reported
that if the cost of zoledronic acid was lowered by 30%,
zoledronic acid could be a cost-effective option compared
with alendronate. Additionally, Karnon et al. [14] indicated that there is a near-zero probability that denosumab
is cost effective at a threshold of $100,000/QALY compared with alendronate at the current price; however, if the
price of denosumab was reduced by 50%, the incremental
cost per QALY gained falls to $50,068.
3.4.4 Medication Adherence/Persistence
Anti-osteoporosis medications have shown to be effective in
reducing fracture risk; however, as a chronic disease, nonadherence to pharmacological treatment in osteoporosis is
a well-recognized problem, which would result not only in
deteriorating clinical outcomes, but also in decreased cost
effectiveness of pharmacotherapy. Several studies [18, 20,
27, 29, 31, 34] reported that the persistence and adherence
rates of osteoporosis medications have marked effects on
the cost-effectiveness ratios. For instance, Mori et al. [18]
indicated that denosumab was cost effective or even cost
saving in comparison with weekly oral alendronate, mainly
driven by the higher persistence rate of denosumab leading
to higher efficacy. In addition, Hiligsmann et al. [27] also
reported that the ICERs of gastro-resistant risedronate were
markedly affected by the incremental difference in persistence between gastro-resistant risedronate and the active
comparator treatment. Moreover, the study of Chen et al.
[31] demonstrated that medication persistence and adherence had a great impact on clinical and cost effectiveness,
high raloxifene persistence and adherence improved clinical effectiveness, but the costs were also higher. Raloxifene
treatment became cost effective compared with a conventional treatment strategy if raloxifene persistence and adherence decreased by 30–50%.

4 Discussion
This updated review identified 27 economic evaluations
of drugs for osteoporosis published between July 2013
and 2019. Twelve active drugs were assessed in the studies, including bisphosphonates (alendronate, etidronate,
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Fig. 2  Proportion of studies meeting individual items recommended in ESCEO-IOF guideline (total studies: 27). BMD bone mineral density,
QALY quality-adjusted life-year, RCTs randomized controlled trials

risedronate, gastro-resistant risedronate, ibandronate, and
zoledronic acid), romosozumab, raloxifene, strontium
ranelate, denosumab, teriparatide, and abaloparatide.
When compared with traditional oral bisphosphonates,
67% of the studies (eight of the total 12 studies) or 82% of
the comparisons (23 of the total 28 comparisons) showed
that the alternative drugs (denosumab, zoledronic acid,
gastro-resistant risedronate, and teriparatide) were cost
effective or dominant at the WTP threshold of US$100,000
per QALY gained. In particular, most studies suggested
that denosumab was a cost-effective or dominant option
compared with oral bisphosphonates. It should however
be noted that recent studies have shown a rapid decrease
of BMD and an increased risk of vertebral fractures after
discontinuation of denosumab [37, 38] and that these
effects have not been included in economic evaluations;
accordingly, the cost effectiveness of denosumab could
be over-estimated.
Additionally, within the total 27 studies, the source of
funding and the role of the funder were fully reported in only
14 studies. It is further interesting to note that three [22, 25,
26] out of eight studies conducted comparing denosumab

with oral bisphosphonates, showing that denosumab was
cost effective or dominant, were funded by industry. For the
remaining five studies that did not mention funding or had
no funding, only three (60%) indicated that denosumab was
cost effective or dominant. The potential bias in industrysponsored studies may therefore exist; however, given the
limited studies, it is difficult to draw a clear conclusion.
Previously, another study [39] comparing economic evaluations of bisphosphonates for the treatment of osteoporosis
suggested that the funding source (industry vs non-industry)
did not seem to significantly affect the reporting of ICERs
below the US$20,000 and US$50,000 thresholds.
Furthermore, some new formulations of bisphosphonates
also led to a higher health benefit than traditional oral tablet
bisphosphonates. One of the included studies showed that
gastro-resistant risedronate was cost effective when compared with traditional oral alendronate [27]. In addition,
some recent studies also indicated that new effervescent
formulation of alendronate could be an intriguing option in
reducing the occurrence of adverse gastrointestinal events
in anti-osteoporosis treatment, thus increasing adherence
to therapy and anti-fracture efficacy [40]. More research is
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Table 6  Quality of reporting of published articles assessing the cost effectiveness of drugs for osteoporosis using the ESCEO-IOF osteoporosis specific checklist
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needed to investigate both the clinical and economic benefits
of these new formulations of oral bisphosphonates.
With emerging evidence about the value of sequential
therapy [41, 42], sequential therapy was included in three
studies [16, 20, 28]. When mutually comparing anabolic
agents, sequential treatment starting with abaloparatide followed by alendronate was shown to be dominant compared
with sequential therapy starting with teriparatide followed
by alendronate. These three studies also compared the cost
effectiveness of sequential therapy with no treatment, placebo, or alendronate alone, indicating mixed results. Incremental cost-effectiveness ratios were strongly affected by
the extremely high drug costs of anabolic agents. One study
[20] demonstrated that their results were sensitive to the
cost of teriparatide, reporting that the cost of a generic/biosimilar product needed to be 65–85% lower than the brand
for sequential teriparatide/alendronate to be cost effective.
After our search period, another study suggested that
sequential treatment starting with abaloparatide followed
by alendronate was cost effective in comparison to generic
alendronate monotherapy for US postmenopausal women
aged ≥ 60 years at an increased risk of fractures. This also
dominated sequential treatment starting with alendronate
followed by abaloparatide and then again by alendronate
[43].
This review updates a previous systematic review of costeffectiveness analyses of drugs for postmenopausal osteoporosis [6]. The previous review identified 39 economic evaluations of drugs in postmenopausal osteoporosis published in
the period 2008–13, an average of 6.5 studies per year. In
our review, 4.5 studies per year were identified. Given that
new osteoporosis medications continue to emerge on the
market, the previous review does not include some medications that were not available that time, but are currently
frequently used. The cost effectiveness of some medications
was not conclusive because of the limited number of studies
in the previous review, but the evidence became clearer in
our updated review. In addition, with newer evidence being
available after the publication of the previous review, the
comparator in the economic evaluation might also changed.
For example, vitamin D and calcium (or no treatment) were
common comparators in previous studies. However, most
studies (74%) in our review made comparisons between
active osteoporotic interventions and traditional oral bisphosphonates, as well as mutual comparisons between different
alternatives.
Moreover, in comparison with the previous review,
where evaluations were mainly conducted in Europe, many
evaluations in the updated review were conducted outside
of Europe and especially in Asia, where osteoporosis is an
increasing burden [44]. Thirty-three percent of the studies
in our review applied the Markov microsimulation model in
comparison with 21% in the previous review, indicating the
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increasing use of Markov microsimulation model in recent
years, which supports the suggestion that the Markov microsimulation model is an evolution of a health economic model
used in osteoporosis. The Markov individual state-transition
model overcomes the memory-less nature of the Markov
cohort model and is preferred to capture all the interactions
between events and the changing risks of future fractures
and mortality [45].
There are several extra findings identified in our review
in comparison with the previous review. However, a comparison between the two studies remains difficult owing to
the large heterogeneity in country setting, model structure,
fracture risk, drug costs, and incorporation of medication
adherence. In addition, the use of FRAX® or GARVAN®
tools [46] indicates a slight increase (5%) in comparison
with studies included in the previous review, but it is still
inadequate (22%).
To assess the quality of included studies, unlike the
general checklist applied in the previous review, we used
an osteoporosis-specific guideline [7] to critically appraise
the studies included in this review. In comparison with
the general quality assessment tools relied on in the previous review, the osteoporosis-specific guideline serves as
a minimum standard for all economic analyses in osteoporosis; the guideline’s specificity enables better identification of unmet quality issues within recent studies and
indicates some highly important criteria that should be met
and improved in future studies, and further helps to reduce
inter-study heterogeneity, thereby facilitating inter-study
comparisons. Although a few studies followed several of
the guideline’s recommendations, given that most of the
studies were published prior to the osteoporosis-specific
guideline, the guide was not available to assist researchers
in designing appropriate and high-quality economic evaluations, which may be why most studies did not adhere
to several recommendations/criteria of the guideline and
scored poorly for some criteria. Room for improvement
was observed.
With regard to osteoporosis-specific recommendations,
the frequently unmet/unreported recommendations such as
‘an additional effect after multiple fractures on cost and/
or utility’, ‘important adverse events’, and ‘a proportion of
excess mortality attributed to the fracture’ should be modeled/included in future studies. As for osteoporosis-specific
checklist for reporting, considering several partially or not
reported recommendations including ‘treatment side effects’,
‘medication adherence’, and ‘treatment effect after discontinuation’ would limit transparency, comparability, and use
by decision maker; these missing or partially reported recommendations should receive more attention and be modeled/included in future studies. Therefore, the osteoporosisspecific guideline, which supplements the generally accepted
methodologic standards, can be useful in improving the
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transparency, quality, and comparability of economic evaluations in osteoporosis, thus increasing its potential for use by
decision makers and leading to a more effective allocation
of resources [7].
Moreover, it is important that researchers should be aware
of and use the guideline. Interestingly, since the publication of the ESCEO-IOF guideline (between October 2018
and August 2020), nine economic evaluations have used
and referenced the guideline. Specifically, these nine studies all reported that the conduct of the economic evaluation adheres to this recent published osteoporosis-specific
guideline. However, only four studies [20, 28, 34, 47] clearly
showed how their studies followed the recommendations of
the guideline. Therefore, to successfully implement this
guideline, we recommend that future studies include a table
in the main text or appendix stating clearly how the criteria
were met, and/or the reasons for non-adherence (if appropriate), which would lead to improved study transparency.
Additionally, some key drivers of cost effectiveness were
identified in this review, including baseline fracture risk,
drug effect on the risk of fractures, drug cost, and medication adherence/persistence. These key drivers were frequently reported to be the most influential factors in the costeffectiveness ratio, and should therefore be incorporated in
future economic evaluations.
Although the present study followed recommendations
for conducting reviews of economic evaluations [48], there
may have been some potential limitations to our study. First,
because of limited space in Table 2 and for clarity, only
base-case results were included in our results analysis. Second, reviewers involved in the quality assessment proposed
different opinions in scoring for some recommendations;
discrepancies in rating were resolved by a third reviewer
(MH) and reached a consensus with the first author (NL). In
addition, differentiating between partially or fully reported
was difficult for some recommendations; the final interpretation/assessment was performed by the first author in agreement with a third reviewer (MH), who assessed all papers.
Third, although the osteoporosis-specific guideline aimed
to complement and align with most general guidelines for
economic evaluations, some differences can be observed.
For instance, the ESCEO-IOF guideline treats one-way and
probabilistic sensitivity analyses equally in scoring, while
other guidelines may treat them separately. Fourth, some
key drivers of cost effectiveness were identified during
the review of the articles. We did not perform a systematic quantitative assessment to identify key drivers of cost
effectiveness.
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5 Conclusions
In comparison with evaluations listed in a previous review,
recent economic evaluations were conducted in more countries, and included more active drugs and sequential therapy
as comparators. A comparison between studies remains difficult. In total, this updated review included 27 studies on
the cost effectiveness of drugs for osteoporosis, suggesting that some active interventions (denosumab, zoledronic
acid, gastro-resistant risedronate, or teriparatide) were cost
effective or dominant when compared with oral bisphosphates. However, given the limited number of studies on
the cost-effectiveness of sequential therapy that have been
conducted so far, further research would be needed to investigate adequate evidence of the beneficial effect of this new
form of intervention over single anti-osteoporosis interventions alone. In addition, the results of a quality appraisal
indicate that greater adherence to the osteoporosis-specific
guideline is expected to improve the transparency, quality,
and comparability of future studies.
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